Parathyroid hormone (1-34) (human) |
カタログ番号GP10069 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 52232-67-4
Sample solution is provided at 25 µL, 10mM.
評判の良い論文で引用されたGlpBio製品
Product Documents
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Protocol
Animal experiment: |
Rats[1]Teriparatide is administered daily to 4-week-old male rats for 1, 2, or 4 weeks with different concentrations (10, 40 μg/kg). At each time point, longitudinal growth, expressed as maximal femur length, is not statistically different between treated and control rats or between the two different treatment groups. Midfemur diaphyseal widths also do not differ between groups[1]. Rabbits[2]Forty-two female New Zealand white rabbits (17-21 weeks old) are used throughout the study. After 10 days of adaptation to their new environment, the rabbits (18-22 weeks old) are randomized into six groups of 7 animals each using the stratified weight method, as follows: 4-week vehicle administration group (4W-Veh), 4-week Teriparatide (TPTD) administration group (4W-Teriparatide: 20 μg/kg, subcutaneously [s.c.], daily), 12-week vehicle administration group (12W-Veh), 4-week Teriparatide administration + 8-week vehicle administration group (4W-Teriparatide + 8W-Veh), 4-week Teriparatide administration + 8-week lower-dose IBN administration group (4W-Teriparatide + 8W-IBN(L): 20 μg/kg of IBN, s.c., every 4 weeks), and 4-week Teriparatide administration + 8-week higher-dose IBN administration group (4W-Teriparatide + 8W-IBN(H): 100 μg/kg of IBN, s.c., every 4 weeks)[2]. |
References: [1]. Frolik CA, et al. Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats. J Bone Miner Res. 1999 Feb;14(2):163-72. |
Cas No. | 52232-67-4 | SDF | |
Formula | C181H291N55O51S2 | M.Wt | 4117.75 |
溶解度 | ≥399.3mg/mL in DMSO, ≥19.88 mg/mL in Water | Storage | -20°C, away from moisture and light |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Complete Stock Solution Preparation Table
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.2429 mL | 1.2143 mL | 2.4285 mL |
5 mM | 0.0486 mL | 0.2429 mL | 0.4857 mL |
10 mM | 0.0243 mL | 0.1214 mL | 0.2429 mL |
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Related Products
- GP10084 type II collagen fragment
- GP10034 survivin (baculoviral IAP repeat-containing protein 5) (21-28)
- GP10068 surface antigen (208-215) [Hepatitis B Virus]
- GP10161 Proteinase K
- GP10072 Pro-Adrenomedullin (153-185), human
- GP10107 Gap 26
- GP10153 V5 Epitope Tag Peptide
- GP10045 Angiotensin 1/2 (2-7)
- GP11075 Imipenem
- GP10157 VSV-G Peptide
- GP10099 amyloid A protein fragment [Homo sapiens]
- GP10014 parathyroid hormone (7-34) [Homo sapiens]/[Macaca fascicularis]
- GP10146 ferritin heavy chain fragment [Multiple species]
- GP10083 Beta-Amyloid (1-11)
- GP10088 Luteinizing hormone releasing hormone human acetate salt (LHRH)
- GP10160 Oritavancin(LY-333328)
- GP10051 Beta-Lipotropin (1-10), porcine
レビュー
Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *